Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs

• Published in: Emerging infectious diseases Vol. 27; no. 3; pp. 985 - 987
• Main Authors: Farooq, Hamzah Z, Cirillo, Daniela M, Hillemann, Doris, Wyllie, David, van der Werf, Marieke J, Ködmön, Csaba, Nikolayevskyy, Vlad
• Format: Journal Article
• Language: English
• Published: United States U.S. National Center for Infectious Diseases 01.03.2021; Centers for Disease Control and Prevention
• Subjects: antimicrobial resistance; bacteria; Consortia; Disease prevention; Drug resistance; Drug resistance in microorganisms; drug susceptibility; for Susceptibility to New Drugs; Genomes; Health aspects; Identification and classification; Infectious diseases; Laboratories; Limited Capability for Testing; Microbial sensitivity tests; Mycobacterium tuberculosis; Public health; Reference services; Research Letter; Tuberculosis; tuberculosis and other mycobacteria; Virology; Europe; United Kingdom > UK; Mycobacterium tuberculosis; bacteria; antimicrobial resistance; drugs; Europe; drug susceptibility; testing; tuberculosis; tuberculosis and other mycobacteria; public health; respiratory infections
• ISSN: 1080-6040; 1080-6059
• DOI: 10.3201/eid2703.204418

We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited.